|
Home
Melanoma Cells
LifeForce Res
Cancer Types
Breast Cancer
Lung
Cell
| |
Cancer Treatment -- (AMYLOXINE®)
Controls
Metastasis
Metastasis the process by which malignant neoplasms can shed individual
cells, which can travel through the lymph vessels or blood vessels, lodge in some distant
organ, and grow into tumors in their own right. There are two major routes of metastasis,
1) hematogenous, in which the cells travel through the blood vessels, and 2)lymphogenous,
in which the lymphatic vessels conduct the cancer cells. In the case of lymphogenous
metastasis, the metastatic tumors can grow from cancers cells entrapped in the lymph nodes
that collect the lymph draining from the organ where the original cancer has developed,
causing the nodes to enlarge. In the case of breast cancer, the axillary (underarm) nodes
are the first to become involved. In the case of cancer of the larynx (voice box), the
nodes on either side of the neck (cervical nodes) are first. Hematogenous metastases
tend to deposit in the lungs, liver, and brain. Many cancers metastasize both
lymphogenously and hematogenously. Most cancer operations attempt to remove not only the
cancerous organ, but also the lymph nodes that drain that organ. Some types of cancer,
especially the common ones (lung, breast, colon, and prostate cancers) tend to metastasize
to lymph nodes first.
The first object of our study was to control Metastasis, in which cells from the tumor,
seed out to other parts of the body and then grow to tumors themselves, and/or para
neoplastic syndromes, in which the neoplasm secretes metabolic poisons or inappropriately
large amounts of hormones that cause problems with functions of various body systems.
Biological control was ruled out due to adverse side effects. Leaving chemical control as
the only logical choice. After studying numerous compounds, ozonides of terpenes
hydrocarbons were studied. Terpenes are widespread in nature, mainly in plants as
constituents of essential oils. Many terpenes are hydrocarbons, but oxygen-containing
compounds such as alcohols, aldehydes or ketones (terpenoids) are also found. Their
building blocks is the hydrocarbon isoprene,CH2=C(CH3)-CH=CH2. Terpene hydrocarbons
therefore have molecular formulas (C5H8)n, they are classified according to the number of
isoprene units. The ozonized terpenes contain up to 50% oxygen by weight.
AMYLOXINE® was designed to control Metastasis, penetrate tumor cells,
and inactivate the protoplasm that goes into the cells and feeds the tumor cells. If the
nutritional protoplasm is eliminated, the cancer cell starves to death. AMYLOXINE®
has three oxygen atoms replacing the double bonds at sites of unsaturation, creating
trioxyacyclopentane. Thereby creating a highly reactive compound, the O3 as such will not
be found in the red blood cell since it is not able to pass the cellular membrane. The red
blood cell will react to the peroxide immediately for being a cytotoxin, and will activate
its detoxification mechanism through the glutathione system. In order to keep up its
system protecting the red blood cell against oxidation, the amount of glutathione consumed
must be reproduced, which is done through a bypath of glycolysis, i.e. the pentose
phosphate path way (PPW). The main task of the pentose phosphate pathway is to protect the
hemoglobin against oxidation into methemoglobin and hence to keep up the function enabling
the transmission of Oxygen. In turn, this means that the entire erythrocyte metabolism is
stepped up. So that any cells of the tumor will be effectively oxidized and eliminated
from the body. This is accomplished with site blocks injections, and IV drip of AMYLOXINE®.
Penetration of cell tumor was achieved with the addition of a solvent, that had no action
on the tumor cell itself, but used as a vehicle, penetrating the tissues to carry AMYLOXINE®
to the protoplasm thereby inactivating and therefore starved the cancer cells to death.
Because of AMYLOXINE® alkaline nature, it is tumor specific to the
nucleic acid of tumor cells. After prolonged IV drip AMYLOXINE® collects
in the nucleus of cancer cells. Normal cells have the ability to absorb and transpose AMYLOXINE®
from there nucleus.
AMYLOXINE® has been used for the past two years on breast cancer
patients. With a 92% remission rate, by injection only, thereby eliminating surgery.
Response to AMYLOXINE®, by other forms of cancer, are now being studied.
It took over four years to get AMYLOXINE® to clinical trials stage with
as estimated cost of developing the new drug at $2.5 million to $3.8 million, excluding
personnel costs. Further multi-agent randomized trials must still be conducted before the
therapy will be approved by the FDA and available for general use in the United States.
Chemical companies are also very interested in AMYLOXINE® for commercial
applications.
LifeForce Research is also studying other biologic sources of therapeutic agents:
enzymes, proteins, and hormones which originate in animal, plants, or humans.
AMYLOXINE® is not yet available for general use in the United States.
This is where we'll announce the most recent additions to our web site. If you've visited
us before and want to know what's changed, take a look here first. |
|
|
